

Q2 Report 2020

Webcast August 13th, 2020

Presenters:

Renée Aguiar-Lucander, CEO

Fredrik Johansson, CFO

Johan Häggblad, CSO

Disclaimer

Important information

This presentation has been prepared by Calliditas Therapeutics AB (publ) (the “Company”) and is furnished to you solely for your information and may not be reproduced or redistributed, in whole or in part, to any other person. By attending the meeting where this presentation is made, or by reading the presentation slides, you agree to be bound by the following limitations. This presentation and any materials distributed in connection with this presentation are not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction. This presentation does not constitute an offer to sell or a solicitation of any offer to buy any securities issued by the Company and neither this presentation nor anything contained herein shall form the basis of, or be relied upon in connection with, any contract or commitment whatsoever. Any securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), or under the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold within the United States absent registration under the Securities Act or exemption from the registration requirement thereof. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. Any securities referred to herein cannot be offered, sold, pledged or otherwise transferred, directly or indirectly, within or into the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act. This presentation does not constitute a “prospectus” within the meaning of the U.S. Securities Act or the Swedish Financial Instruments Trading Act. This presentation is only being provided to persons that are (i) “Qualified Institutional Buyers”, as defined in Rule 144A under the U.S. Securities Act, or (ii) outside the United States. By attending this presentation or by reading the presentation slides, you warrant and acknowledge that you fall within one of the categories (i) and (ii) above. Any securities referred to herein have not been and will not be registered under the applicable securities laws of Canada, Australia or Japan and may not be offered or sold within Canada, Australia or Japan or to any national, resident or citizen of Canada, Australia or Japan. The distribution of this presentation in other jurisdictions may be restricted by law and persons into whose possession this presentation comes should inform themselves about, and observe, any such restrictions. This presentation contains various forward-looking statements that reflect the Company’s current views with respect to future events and financial and operational performance. The words “believe,” “expect,” “anticipate,” “intend,” “may,” “plan,” “estimate,” “should,” “could,” “aim,” “target,” “might,” or, in each case, their negative, or similar expressions identify certain of these forward-looking statements. Others can be identified from the context in which the statements are made. These forward-looking statements involve known and unknown risks, uncertainties and other factors, which are in some cases beyond the Company’s control and may cause actual results, development or performance to differ materially from those expressed or implied from such forward-looking statements. The information and opinions contained in this document are provided as at the date of this presentation and are subject to change without notice, and neither the Company nor any other person are under any obligation to update the presentation, except as provided for in applicable laws and/or stock exchange regulations. No representation or warranty (expressed or implied) is made as to, and no reliance should be placed on, the fairness, accuracy or completeness of the information contained herein. Accordingly, none of the Company or any of its principal shareholders or subsidiary undertakings or any of such person’s officers or employees accepts any liability whatsoever arising directly or indirectly from the use of this document. Except as explicitly stated herein, no information in this document has been audited or reviewed by the Company’s auditors. Certain financial and other numerical information presented in this presentation have been subject to rounding adjustments for the purpose of making this presentation more easily accessible for the reader. As a result, the figures in tables may not sum up to the stated totals.

Summary of key events Q2 2020

- In June, Calliditas completed an initial public offering on The Nasdaq Global Select Market in the United States for gross proceeds of approximately USD 90 million (SEK 828 million).
 - Became the first Swedish life science company to raise capital in an IPO on NASDAQ Select
 - Significant demand
 - multiple times oversubscribed
 - high quality US investors
 - Upsized deal from USD 75 M to 90M due to demand
 - 90% of deal placed with US investors
- In April, Calliditas appointed Dr. Richard Philipson as Chief Medical Officer (CMO)
 - Strong background in orphan drug development
 - Over 16 years at GSK, including Head and Acting CMO of GSK rare disease unit
 - Recently managed the FDA filing process of an orphan drug candidate for Trizell Ltd
 - 25 years of professional experience: combination of big pharma experience and smaller biotech environment
- Change in Board composition at the AGM in June; election of Molly Henderson to the Board of Directors.

Covid-19

- COVID-19 continues to create havoc across the globe
 - The World Health Organization (WHO) on March 11, 2020, declared the novel coronavirus (COVID-19) outbreak a global pandemic.
 - The virus has continued to spread across North and South America as well as in India
 - At the time of our last quarterly report we quoted numbers of 4 million cases; today this is in excess of 20 million
 - Total Deaths Worldwide at the same time were 290,000; today the tally stands at over 730,000
 - In May the US reported over a million cases and over 80,000 deaths; today those numbers are 5 million and over 160,000 respectively
 - The new virus seems to be more of a clotting disorder rather than a respiratory disease in general and continues to baffle the medical community, despite enormous resources being thrown at it.
 - However, slowly but surely science is making progress, and there has been a significant reduction in mortality.
 - Government backed initiatives into vaccines have exceeded \$8bn already with an expectation that towards the end of the year, early next year, some parts of the world will have some kind of vaccine
 - Over 700 clinical trials are presently underway and more are being added on a daily basis

Covid-19 business impact in Q2


- Phase 3 study continues to be on plan
 - Over 146 clinical sites activated and recruiting across 19 countries
 - In Q2 continued focus on analyzing potential impact of the virus across different geographic regions and crafting mitigating solutions to ensure patient safety and trial integrity.
 - Significant improvement seen in June compared to April
 - Limited impact to date on NeflgArd:
 - Part A fully recruited in December 2019
 - Oral medication
 - Limited interaction with healthcare system
 - Successful implementation of strategy encompassing CRO, national co-ordinators and site staff to minimize potential impact
 - Helpful guidance received from regulatory bodies
 - Part B:
 - Recruitment rate has been impacted in Q2, but improvements seen across Europe and Asia
 - Completion of recruitment still possible before the end of the year with China contribution, however the ongoing situation in the US is still a concern

Post quarter events

- Partial exercise of the greenshoe resulting in an additional capital infusion of USD 6.9 million (SEK 63 million)
- Research coverage initiated by Citi, Jefferies and Stifel in the US, significantly expanding research coverage
- Expansion of pipeline:
 - Announcement of agreement to acquire controlling stake in Genkyotex SA, followed by a mandatory simplified tender offer subject to closing of the controlling stake
 - €20.3m in total consideration at €2.80/share for 62.7% of the company
 - Contingent rights amounting to a total of €55M related to regulatory approvals of setanaxib within a 10 year period:
 - €30M for FDA approval,
 - €15M for EMA approval,
 - €10M for either IPF or type 1 diabetes approval by either FDA or EMA (unless milestone paid out as per above).
 - Following the closing of the control transaction, a simplified cash tender offer will be launched on the same terms for the remaining outstanding shares. The off-market block trade is expected to close in early October 2020.
 - Delivering on our communicated strategy; acquiring a late stage asset with orphan focus
 - Genkyotex's lead clinical candidate, setanaxib (GKT831), is in development for Primary Biliary Cholangitis (PBC), and in a Phase 2 trial demonstrated evidence of anti-fibrotic activity and significant impact on fatigue
 - Broad platform with potential to address inflammatory / fibrotic disease across a variety of indications
 - No significant impact on cash runway


NOX enzymes

- NADPH oxidases (NOX enzymes) are critical mediators of both physiologic and pathophysiologic processes
- NOX enzymes catalyze NADPH-dependent generation of reactive oxygen species (ROS), including superoxide and hydrogen peroxide
- NOX enzymes are a family of seven (7) enzymes that amplify signalling pathways
- NOX 1 and NOX 4 are involved in inflammatory and fibrotic pathways, respectively




NOX enzymes and drug development

- Oxidative stress, an excess of ROS production vs. consumption, is involved in the pathogenesis of different diseases
- At appropriate concentrations ROS serve essential functions in cellular signalling processes of eg proliferation, differentiation, migration, vascular tone, immune response etc
- Enhanced activity of ROS production may cause systems to overreact and drive eg pathogenic inflammation and fibrosis
- NOX enzyme inhibitors are a class of very promising novel experimental drugs in redox pharmacology
- Inhibitors of NOX 1 and NOX 4 are relevant therapeutic agents for inflammatory and fibrotic diseases, an area of high unmet medical need
- NOX pharmacology is a developing field with approx 1,500 peer reviewed reports the past 10 years (PubMed)



Financial overview – First six months of 2020



- Revenues of SEK 0.5M vs SEK 138.2M for the same period last year.
- Operating profit/(loss) of (SEK 138.9M) vs SEK 42.7M
 - Research and development expenses increased to SEK 102.5M vs SEK 61.9M, representing 74% of total operating expenses. Increase due to higher activity in the NeflgArd study and product development.
 - Sales and administrative expenses increased to SEK 36.8M vs SEK 28.8M, mainly due to increase in pre-commercial activities and expenses in connection with the June NASDAQ listing.
- Cash flow used in operating activities was SEK 85.8M vs SEK 108.7M, due to receipt of USD 5M payment in Q1 for Q4 2019 China milestone.
- Cash position per end of June 2020 was SEK 1,459.6M vs SEK 534.9M. The increase is due to the cash flow from financing activities of SEK 777.7 M primarily from the Nasdaq IPO.

Anticipated milestones

Anticipated milestones regarding Calliditas' clinical, regulatory and commercial plans

1H 2018	2H 2018	1H 2019	2H 2019	2020*	2021	2022
<ul style="list-style-type: none"> IPO raising \$82m on Nasdaq OMX <input checked="" type="checkbox"/> 	<ul style="list-style-type: none"> NeflgArd first patient in <input checked="" type="checkbox"/> Application for Orphan Drug Designation (ODD) for PBC submitted <input checked="" type="checkbox"/> Application for ODD for AIH submitted <input checked="" type="checkbox"/> 	<ul style="list-style-type: none"> Filing of Pediatric Investigational Plan submitted to EMA <input checked="" type="checkbox"/> Approval of ODD designation for PBC <input checked="" type="checkbox"/> Approval of ODD designation for AIH <input checked="" type="checkbox"/> 	<ul style="list-style-type: none"> EMA meeting to discuss surrogate marker <input checked="" type="checkbox"/> Fully recruited Part A of NeflgArd with 200 patients <input checked="" type="checkbox"/> China IND approval for Nefecon in IgAN, triggering \$5mm milestone <input checked="" type="checkbox"/> EMA positive opinion regarding pediatric pathway for Nefecon in IgAN <input checked="" type="checkbox"/> 	<ul style="list-style-type: none"> In-licensing of a new project to the pipeline <input checked="" type="checkbox"/> Topline readout of Part A of NeflgArd for 200 patients (4Q 2020) Initiate open-label extension trial for Nefecon in IgAN (4Q 2020) Complete recruitment of Part B of NeflgArd trial of additional 160 patients FDA feedback regarding regulatory pathway for AIH China part of phase 3 recruitment initiated 	<ul style="list-style-type: none"> NDA / MAA filings with FDA and EMA for accelerated / conditional approval of Nefecon in IgAN (1H 2021) Late stage clinical program initiated Initiate open-label extended dosing trial for Nefecon in IgAN 	<ul style="list-style-type: none"> Commercial launch of Nefecon for IgAN in U.S. (1H 2022) Readout of Part B of NeflgArd trial based on 360 patients for validation of surrogate marker to support full approval (2022)*

* Subject to uncertainty due to the Covid-19 outbreak

Investment highlights

- 1 Nefecon is a proprietary, novel treatment for IgAN intended to be **disease modifying**
- 2 Nefecon targets the presumed **origin** of the disease – the area of the ileum where the highest concentration of Peyer's patches are located
- 3 Nefecon is the **most advanced** product candidate for IgAN. The **only successful** randomized, double-blind, placebo-controlled Phase 2b clinical trial carried out in IgAN to date
- 4 Ongoing pivotal Phase 3 clinical trial (NefIgArd) **using the same primary endpoint** as previous successful Phase 2b trial
- 5 Regulatory pathway based on discussions with FDA and EMA of our seeking accelerated / conditional approval based on proteinuria as **surrogate marker** for IgAN
- 6 **Significant unmet medical need** in IgAN with no currently approved treatments; total market opportunity of US\$9-10bn in the U.S alone.
- 7 Additional potential for **pipeline development** and **in-licensing** of product candidates targeting orphan diseases



Questions